Adamantinoma

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:55881OMIM:102660C40.2
Who is this for?
Show terms as
4Active trials31Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Adamantinoma is a very rare type of bone cancer that almost always develops in the long bones of the legs, most often in the shinbone (tibia). It can also occur in the fibula (the smaller bone next to the shinbone) and, rarely, in other bones. The tumor grows slowly and tends to stay in the bone for a long time before spreading, which is why it is sometimes called a 'low-grade' malignant tumor. Despite its slow growth, adamantinoma is a true cancer and can spread to other parts of the body, including the lungs and lymph nodes, if not treated. The most common symptoms are pain, swelling, and a firm lump along the shinbone. Many people notice these symptoms for months or even years before getting a diagnosis, because the tumor grows so slowly. The disease most often affects teenagers and young adults, though it can appear at any age. The main treatment is surgery to remove the tumor, usually with a wide margin of healthy tissue around it. In some cases, the affected bone segment is replaced with a bone graft or a metal implant. Radiation and chemotherapy are generally not very effective for this tumor, so surgery is the cornerstone of care. With complete surgical removal, many patients do well, but long-term follow-up is essential because the tumor can come back years later.

Also known as:

Key symptoms:

Pain in the shinbone or lower legSwelling or a lump along the shinboneA firm, hard mass that can be felt under the skinBowing or curving of the lower leg boneTenderness when pressing on the affected areaGradual worsening of leg pain over months or yearsDifficulty walking or bearing weight on the legRarely, a fracture through the weakened boneShortness of breath or cough if cancer has spread to the lungs

Clinical phenotype terms (3)— hover any for plain English
Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗OMIM ↗NORD ↗

FDA & Trial Timeline

5 events
Apr 2025Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma

Nanfang Hospital, Southern Medical University — PHASE1, PHASE2

TrialRECRUITING
May 2023FOG-001 in Locally Advanced or Metastatic Solid Tumors

Parabilis Medicines, Inc. — PHASE1, PHASE2

TrialRECRUITING
Apr 2023MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

Nationwide Children's Hospital — PHASE2

TrialRECRUITING
Dec 2022ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

Nationwide Children's Hospital — PHASE2

TrialRECRUITING
Sep 2019Tocilizumab in Children With ACP

University of Colorado, Denver — EARLY_PHASE1

TrialACTIVE NOT RECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Adamantinoma.

4 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

4 recruitingView all trials with filters →
Phase 22 trials
ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
Phase 2
Actively Recruiting
PI: Holly Lindsay, MD (Children's Hospital Colorado) · Sites: Aurora, Colorado; Washington D.C., District of Columbia +12 more · Age: 139 yrs
MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
Phase 2
Actively Recruiting
PI: Holly Lindsay, MD (Children's Hospital Colorado) · Sites: Aurora, Colorado; Washington D.C., District of Columbia +8 more · Age: 139 yrs

Specialists

Showing 25 of 31View all specialists →
MM
Maryam Fouladi, MD
COLUMBUS, OH
Specialist
PI on 10 active trials
SP
Stanislaw R. Burzynski, MD, PhD
HOUSTON, TX
Specialist
PI on 29 active trials
SM
Sabine Mueller, MD, PhD, MAS
SAN FRANCISCO, CA
Specialist
PI on 8 active trials
TM
Tobey MacDonald
WASHINGTON, DC
Specialist
PI on 2 active trials5 Adamantinoma publications
JM
Jana Portnow, MD
DUARTE, CA
Specialist
PI on 3 active trials
AC
Alexander Colevas
PALO ALTO, CA
Specialist
PI on 2 active trials1 Adamantinoma publication
VP
Valerie Crabtree, PhD
STARKVILLE, MS
Specialist
PI on 2 active trials
AO
Antonio Omuro
STANFORD, CA
Specialist
PI on 1 active trial
YP
yehia A El-Mahallawy, PhD
Specialist
PI on 1 active trial
MK
M Kroesen
MILFORD, MA
Specialist
PI on 1 active trial
AR
A Mendez Romero
Specialist
PI on 1 active trial11 Adamantinoma publications
HW
Hiske van der Weide
Specialist
PI on 1 active trial1 Adamantinoma publication
JJ
J Jaspers
WENATCHEE, WA
Specialist
PI on 1 active trial
KW
Katherine Warren
Specialist
PI on 1 active trial
AG
Amar Gajjar
MEMPHIS, TN
Specialist
PI on 4 active trials4 Adamantinoma publications
HM
Hermann L Müller, MD
Specialist
PI on 1 active trial
TL
TAREK ABDELBARY, Lecturer
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Adamantinoma.

Search all travel grants →NORD Financial Assistance ↗

Community

Open AdamantinomaForum →

No community posts yet. Be the first to share your experience with Adamantinoma.

Start the conversation →

Latest news about Adamantinoma

Disease timeline:

New recruiting trial: Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology

A new clinical trial is recruiting patients for Adamantinoma

New recruiting trial: Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma

A new clinical trial is recruiting patients for Adamantinoma

New recruiting trial: Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma

A new clinical trial is recruiting patients for Adamantinoma

New recruiting trial: Virtual Lesion Segmentation and Mandibular Ameloblastoma Radiographic Safety Margin

A new clinical trial is recruiting patients for Adamantinoma

New recruiting trial: The Impact of Endoscopic Endonasal Skull Base Surgery on Olfaction

A new clinical trial is recruiting patients for Adamantinoma

New recruiting trial: MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

A new clinical trial is recruiting patients for Adamantinoma

New recruiting trial: ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

A new clinical trial is recruiting patients for Adamantinoma

New recruiting trial: Craniopharyngioma and Pregnancies

A new clinical trial is recruiting patients for Adamantinoma

New recruiting trial: Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults

A new clinical trial is recruiting patients for Adamantinoma

New recruiting trial: FOG-001 in Locally Advanced or Metastatic Solid Tumors

A new clinical trial is recruiting patients for Adamantinoma

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.Has the tumor spread beyond the bone, and what tests will you use to find out?,What type of surgery do you recommend, and will I need a bone graft or metal implant?,What are the chances the tumor will come back, and how will we monitor for that?,Will I need chemotherapy or radiation, and why or why not?,How long will my recovery take, and what will physical therapy involve?,Are there any clinical trials I should consider for this type of tumor?,How often will I need follow-up scans, and for how many years?

Common questions about Adamantinoma

What is Adamantinoma?

Adamantinoma is a very rare type of bone cancer that almost always develops in the long bones of the legs, most often in the shinbone (tibia). It can also occur in the fibula (the smaller bone next to the shinbone) and, rarely, in other bones. The tumor grows slowly and tends to stay in the bone for a long time before spreading, which is why it is sometimes called a 'low-grade' malignant tumor. Despite its slow growth, adamantinoma is a true cancer and can spread to other parts of the body, including the lungs and lymph nodes, if not treated. The most common symptoms are pain, swelling, and a

How is Adamantinoma inherited?

Adamantinoma follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

Are there clinical trials for Adamantinoma?

Yes — 4 recruiting clinical trials are currently listed for Adamantinoma on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Adamantinoma?

25 specialists and care centers treating Adamantinoma are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.